Revelation Biosciences is a San Diego clinical-stage company whose residual claim is a call option on Gemini, a proprietary toll-like receptor agonist aimed first at hospital acute kidney injury. The Food and Drug Administration agreed in January that a single adaptive late-stage study with a death-or-dialysis composite can support a new drug application. That is a real regulatory narrowing for a name that spent years as a serial recap vehicle. The market still prices the common below cash, which is the honest read on whether that path gets funded before the residual claim is rewritten again.
The second-quarter print is a start-up quarter, not a proof quarter. Cash finished the period just above $11 million after a January warrant inducement that brought in nearly $7 million, then receded as operating spend stepped up for study preparation. Research spending and overhead both increased as the company staffed the path it just cleared. An independent hospital-market review published in early August argues a large addressable opportunity in severe acute kidney injury, and the company later named Avance Clinical as the contract research organization for the TITAN study. None of that changes the arithmetic that current cash does not finish a multi-hundred-patient hospital trial.
The investment debate is whether the cash discount is a misreading of a cleared path or a correct forecast of the next recap. The bull case needs first-patient enrollment on the year-end timeline plus a financing that does not reset the share count again. The bear case is already visible in four reverse splits, a July stockholder rights plan with a low ownership trigger, and a warrant stack larger than the common. Does TITAN actually open before cash forces another inducement?